NASDAQ:ORPN

Bioblast Pharma (ORPN) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.60
▼
$2.63
50-Day Range: $11.50
▼
$28.49
52-Week Range: $6.16
▼
$30.00

Volume: 26,876 shs
Average Volume: N/A
Market Capitalization: $1.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Financials Institutional Ownership Headlines SEC Filings Social Media

About Bioblast Pharma (NASDAQ:ORPN) Stock

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.

Receive ORPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioblast Pharma and its competitors with MarketBeat's FREE daily newsletter.

ORPN Stock News Headlines

March 31, 2023 | wsj.com

Changzhou Qianhong Bio-Pharma Co. Ltd. A

March 1, 2023 | marketwatch.com

2023 Spinal Muscular Atrophy Medicine Market Report has the Potential to Deliver Genuine Review for Development

June 1, 2023 | Edge On The Street (Ad)

The $193 Billion US-China War You Don't Know About

They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.

February 18, 2023 | marketwatch.com

Spinal Muscular Atrophy Medicine Market Size Global Research Report, 2023 - 2028

February 15, 2023 | marketwatch.com

Spinal Muscular Atrophy Medicine Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028

February 13, 2023 | thestreet.com

BioBlast Scant Data Links Drug to Improved Swallowing in Patients

January 30, 2023 | seekingalpha.com

BioMarin: Opportunity To Score Home Run With Latest Regulatory Advancements

January 18, 2023 | marketwatch.com

Spinal Muscular Atrophy Medicine Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028

June 1, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

October 16, 2022 | finance.yahoo.com

Orphan Drugs Market Size to Hit USD 340.84 Billion by 2027

September 21, 2022 | seekingalpha.com

ENLV Enlivex Therapeutics Ltd.

August 31, 2022 | marketwatch.com

BioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans Progressiva

August 31, 2022 | msn.com

BioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease Candidate

August 12, 2022 | finance.yahoo.com

Aro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe Disease

August 11, 2022 | seekingalpha.com

BioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call Transcript

August 1, 2022 | finance.yahoo.com

Biosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic Syndromes

July 12, 2022 | markets.businessinsider.com

Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell Lymphoma

July 8, 2022 | apnews.com

Global Orphan Drugs Global Market Report (2022 to 2031) - Featuring Amgen, Biogen, Novartis and Novo Nordisk Among Others - ResearchAndMarkets.com

July 7, 2022 | apnews.com

Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA

June 30, 2022 | marketwatch.com

Aura Biosciences Gets Fast Track Designation for AU-011 Bladder Cancer Treatment

June 7, 2022 | markets.businessinsider.com

Prolacta Bioscience Appoints David Steinberg as Chief Financial Officer

May 25, 2022 | apnews.com

ENB Therapeutics Announces Orphan Drug Designation Granted by FDA for ENB-003 for the Treatment of Pancreatic Cancer

May 12, 2022 | finance.yahoo.com

Stealth BioTherapeutics Receives Orphan Drug Designation from FDA for Elamipretide for Treatment of Duchenne Muscular Dystrophy

September 17, 2021 | prnewswire.com

Global Genetic Disorders Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

September 10, 2020 | marketwatch.com

Spinal Muscular Atrophy Medicine Market Share Analysis, Trends, Segmentation, Top Players Analysis, Growth and COVID-19 Impact Forecast by 2020-2026

March 6, 2019 | finance.yahoo.com

Bioblast Announces Effectiveness of Eight to One Reverse Split

February 19, 2019 | seekingalpha.com

BioBlast up 64% on Trehalose deal with Seelos

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ORPN
CUSIP: N/A
CIK: 1596812
Web: bioblastpharma.com
Phone: (722) 670-8072
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.56 per share
Price / Book: 0.35

Miscellaneous

Outstanding Shares: 420,000
Free Float: N/A
Market Cap: $1.10 million
Optionable: Not Optionable
Beta: 1.41

Key Executives

Oren Hershkovitz
Chief Executive Officer

Shachar Shlosberger
Chief Financial Officer

Dror Mevorach
Chief Scientific & Medical Officer

Odelia Ben-Shitrit
Head-Clinical Operations

Key Competitors

View All Competitors

ORPN Stock - Frequently Asked Questions

When did Bioblast Pharma's stock split?: Shares of Bioblast Pharma reverse split on the morning of Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What other stocks do shareholders of Bioblast Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Verastem (VSTM), Voyager Therapeutics (VYGR), Athersys (ATHX), ContraFect (CFRX), CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO).

What is Bioblast Pharma's stock symbol?: Bioblast Pharma trades on the NASDAQ under the ticker symbol "ORPN."
What is Bioblast Pharma's stock price today?: One share of ORPN stock can currently be purchased for approximately $2.62.
How much money does Bioblast Pharma make?: Bioblast Pharma (NASDAQ:ORPN) has a market capitalization of $1.10 million.
How can I contact Bioblast Pharma?: Bioblast Pharma's mailing address is PO Box 318, Tel-Aviv Is, 6100201. The official website for the company is bioblastpharma.com. The biopharmaceutical company can be reached via phone at (722) 670-8072 or via email at ir@bioblastpharma.com.

This page (NASDAQ:ORPN) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Bioblast Pharma (ORPN) Stock Forecast, Price & News

About Bioblast Pharma (NASDAQ:ORPN) Stock

ORPN Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ORPN Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info